Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Yanev I, Gatete J Jr, Aprikian AG, et al. The health economics of metastatic hormone-sensitive and non-metastatic castration-resistant prostate cancer—a systematic literature review with application to the Canadian context. Curr Oncol. 2022;29(5):3393–3424. doi:10.3390/curroncol29050275.
   PubMed Web of Science ®Google Scholar
• Lowrance WT, Breau RH, Chou R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline part I. J Urol. 2021;205(1):14–21. doi:10.1097/JU.0000000000001375.
   PubMed Web of Science ®Google Scholar
• Thapa B, Mahendraker N, Ramphul K. Paraneoplastic syndromes. In: StatPearls (internet). Treasure Island (FL): StatPearls Publishing; 2023. [cited 2023 Aug 30]. https://www.ncbi.nlm.nih.gov/books/NBK507890/
   Google Scholar
• Wang F, Wang C, Xia H, et al. Burden of prostate cancer in China, 1990–2019: findings from the 2019 Global Burden of Disease Study. Front Endocrinol (Lausanne). 2022;13:853623. doi:10.3389/fendo.2022.853623.
   PubMed Web of Science ®Google Scholar
• World Health Organization International Agency for Research on Cancer (WHO-IRAC). Estimated number of prevalent cases in 2020, World, China, both sexes, all ages (excl. NMSC). [cited 2024 Feb]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf.
   Google Scholar
• National Health Commission of the People’s Republic of China. National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):270–288. doi:10.21147/j.issn.1000-9604.2022.03.07.
   PubMed Web of Science ®Google Scholar
• Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. Oncol Ther. 2020;8(2):209–230. doi:10.1007/s40487-020-00119-z.
   PubMed Web of Science ®Google Scholar
• Cattrini C, Castro E, Lozano R, et al. Current treatment options for metastatic hormone-sensitive prostate cancer. Cancers (Basel). 2019;11(9):1355. doi:10.3390/cancers11091355.
   PubMed Web of Science ®Google Scholar
• Gul A, Garcia JA, Barata PC. Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide. Cancer Manag Res. 2019;11:7253–7262. doi:10.2147/CMAR.S165706.
   PubMed Web of Science ®Google Scholar
• Hussain A, Jiang S, Varghese D, et al. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States. BMC Cancer. 2022;22(1):304. doi:10.1186/s12885-022-09364-z.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi:10.1056/NEJMoa1704174.
   PubMed Web of Science ®Google Scholar
• James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi:10.1056/NEJMoa1702900.
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381(1):13–24. doi:10.1056/NEJMoa1903307.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. Prostate. 2019;82(13):1237–1247. doi:10.1200/JCO.19.00799.
   Google Scholar
• Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131. doi:10.1056/NEJMoa1903835.
   PubMed Web of Science ®Google Scholar
• Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–2474. doi:10.1056/NEJMoa1800536.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–1418. doi:10.1056/NEJMoa1715546.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235–1246. doi:10.1056/NEJMoa1815671.
   PubMed Web of Science ®Google Scholar
• China Statistical Yearbook. 2022. Available from https://www.stats.gov.cn/sj/ndsj/2022/indexch.htm
   Google Scholar
• 2021 Average exchange rate. [Internet]. Beijing, China: The People’s Bank of China Statistics and Analysis Department; no copyright date. Available from: http://www.pbc.gov.cn/diaochatongjisi/116219/116319/4184109/4184111/index.html.
   Google Scholar
• Zhang Z, Liang G, Zhang P, et al. China county-based prostate specific antigen screening for prostate cancer and a cost-effective analysis. Transl Androl Urol. 2021;10(10):3787–3799. doi:10.21037/tau-21-779.
   PubMed Web of Science ®Google Scholar
• Chen R, Ren S, Yiu MK, et al. Prostate cancer in Asia: a collaborative report. Asian J Urol. 2014;1(1):15–29. doi:10.1016/j.ajur.2014.08.007.
   PubMedGoogle Scholar
• Chinese Prostate Cancer Consortium and Chinese Urology Association. Chinese expert consensus on early diagnosis of prostate cancer. Chinese J Urol. 2015;36(8):561–564. (Article in Chinese)
   Google Scholar
• Liede A, Arellano J, Hechmati G, et al. International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC). J Clin Oncol. 2013;31(15_suppl):e16052–e16052. doi:10.1200/jco.2013.31.15_suppl.e16052.
   Web of Science ®Google Scholar
• Lv Z, Wang X, Zhu C, et al. The global status of research in prostate cancer bone metastasis: a bibliometric and visualized analysis. Front Med (Lausanne). 2022;9:931422. doi:10.3389/fmed.2022.931422.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2023. Available from: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
   Google Scholar
• Shah R, Ledesma D, Ikeme S, et al. Characteristics and treatment patterns for non-metastatic castration resistant prostate cancer patients in Japan. Ann Oncol. 2019;30(Suppl 6):vi94. doi:10.1093/annonc/mdz338.018.
   Google Scholar
• Leith A, Ribbands A, Kim J, et al. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan. BMC Urol. 2022;22(1):33. doi:10.1186/s12894-022-00979-9.
   PubMed Web of Science ®Google Scholar
• Bai L, Wushouer H, Huang C, et al. Health care utilization and costs of patients with prostate cancer in China based on national health insurance database from 2015 to 2017. Front Pharmacol. 2020;11:719. doi:10.3389/fphar.2020.00719.
   PubMed Web of Science ®Google Scholar
• Yu M, Duan X, Wang J, et al. PCN109 disease burden of metastatic hormone-sensitive prostate cancer (MHSPC) in China. Value Health. 2021;24(Suppl 1):S39–S40. doi:10.1016/j.jval.2021.04.201.
   Google Scholar
• Ma FF, Liu Q, Wang J, et al. PCN162 disease burden of castration-resistant prostate cancer (CRPC) in China. Value Health. 2020;23(Suppl 2):S451–S452. doi:10.1016/j.jval.2020.08.299.
   PubMedGoogle Scholar